DOACs: 60 Second Insights
Published: 18 June 2018
-
Views:
668
-
Likes:
7
-
Views:
668
-
Likes:
7
-
Up Next -
46sPart 1 | Session 2 What factors influence your choice of DOAC?
-
46sPart 1 | Session 3 Do you have a DOAC you prescribe more frequently?
-
46sPart 1 | Session 4 What are the most important anticoagulation clinical trials?
-
45sPart 1 | Session 5 Do you have a DOAC of choice?
-
41sPart 1 | Session 6 How important are reversal agents? - Christoper Cannon
-
42sPart 1 | Session 7 How important are reversal agents? - Moussa Mansour
-
36sPart 1 | Session 8 Are you once-daily or twice-daily? - Christopher Cannon
-
33sPart 1 | Session 9 Are you once-daily or twice-daily? - Moussa Mansour
-
38sPart 1 | Session 10 Is RCT or real-world data more important to you? - Christopher Cannon
-
1m 3sPart 1 | Session 11 Is RCT or real-world data more important to you? - Moussa Mansour
Overview
Christopher Cannon and Moussa Mansour share their thoughts on DOACs in a series of 60-second interviews
More from this programme
Part 1
DOACs
Faculty Biographies
Christopher P Cannon
Professor
Dr Christopher Cannon is a Professor of Medicine at Harvard Medical School, and Senior Physician in the Preventive Cardiology section of the Cardiovascular Division at Brigham and Women’s Hospital.
He earned his MD from Columbia University College of Physicians and Surgeons in New York and did internal medicine residency at Columbia Presbyterian Medical Center, and cardiovascular fellowship at Brigham and Women’s Hospital.
Dr Cannon has published over 1000 original articles, reviews or book chapters in the field of acute coronary syndromes and prevention and has authored or edited 18 books. He has received numerous awards, including leadership awards from the American College of Cardiology, American Heart Association and National Lipid Association.
He has been principal investigator of more than 20 multicenter clinical trials, including TACTICS-TIMI 18, PROVE IT, IMPROVE IT, RE-DUAL PCI and VERTIS CV trials.
Dr Cannon is on the…